These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33205707)

  • 41. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
    Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
    Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
    Holley RJ; Ellison SM; Fil D; O'Leary C; McDermott J; Senthivel N; Langford-Smith AWW; Wilkinson FL; D'Souza Z; Parker H; Liao A; Rowlston S; Gleitz HFE; Kan SH; Dickson PI; Bigger BW
    Brain; 2018 Jan; 141(1):99-116. PubMed ID: 29186350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mucopolysaccharidosis IIIB (Sanfilippo syndrome B) in a commercial emu (Dromaius novaehollandiae) flock.
    Genger SC; Mizukami K; Martin MP; Applegate JR; Barnes HJ; Giger U
    Avian Pathol; 2018 Feb; 47(1):100-107. PubMed ID: 28911234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted Metabolomic Analysis of a Mucopolysaccharidosis IIIB Mouse Model Reveals an Imbalance of Branched-Chain Amino Acid and Fatty Acid Metabolism.
    De Pasquale V; Caterino M; Costanzo M; Fedele R; Ruoppolo M; Pavone LM
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.
    Ohmi K; Greenberg DS; Rajavel KS; Ryazantsev S; Li HH; Neufeld EF
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1902-7. PubMed ID: 12576554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
    Zhang H; Wood T; Young SP; Millington DS
    Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C.
    Pshezhetsky AV
    Autophagy; 2016 Jun; 12(6):1059-60. PubMed ID: 25998837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathology of mucopolysaccharidosis IIIA in Huntaway dogs.
    Jolly RD; Johnstone AC; Norman EJ; Hopwood JJ; Walkley SU
    Vet Pathol; 2007 Sep; 44(5):569-78. PubMed ID: 17846229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Engineered
    Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.
    Herati RS; Knox VW; O'Donnell P; D'Angelo M; Haskins ME; Ponder KP
    Mol Genet Metab; 2008 Nov; 95(3):142-51. PubMed ID: 18707908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
    Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
    J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response.
    Killedar S; Dirosario J; Divers E; Popovich PG; McCarty DM; Fu H
    J Neuroinflammation; 2010 Jul; 7():39. PubMed ID: 20637096
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebellar tumour-like aggregate of glycosaminoglycans in a MPS IIIB patient: a case report.
    de Laurentis C; Gasperini S; Chiarello G; Motta S; Canonico F; Giussani CG
    Childs Nerv Syst; 2020 Sep; 36(9):2093-2097. PubMed ID: 31965290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
    Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood.
    Naughton BJ; Duncan FJ; Murrey D; Ware T; Meadows A; McCarty DM; Fu H
    PLoS One; 2013; 8(11):e80142. PubMed ID: 24278249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultrastructural analysis of different skeletal cell types in mucopolysaccharidosis dogs at the onset of postnatal growth.
    Jiang Z; Lau YK; Wu M; Casal ML; Smith LJ
    J Anat; 2021 Feb; 238(2):416-425. PubMed ID: 32895948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
    Lau YK; Peck SH; Arginteanu T; Wu M; Lin M; Shore EM; Klein PS; Casal ML; Smith LJ
    Bone; 2022 Jan; 154():116237. PubMed ID: 34695616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.